
Court Ruling Limits Ozempic Copies in Favor of FDA, Novo Nordisk
A federal court in Texas has
The ruling, issued April 24 in the U.S. District Court for the Northern District of Texas, denied a request from the Outsourcing Facilities Association (OFA) to block the FDA's recent
That decision effectively ended a temporary allowance for pharmacies to compound semaglutide-based drugs for patients. Semaglutide is the active ingredient in Ozempic and Wegovy. Court documents remain
According to a KFF
Without the shortage designation, pharmacies may no longer produce compounded versions of semaglutide except in rare circumstances. Smaller 503A pharmacies must stop immediately, while larger outsourcing facilities have until May 22 before facing FDA enforcement.
The FDA
said in
had been in shortage since 2022 due to 'increased demand.'
Related Stories
2/24/2025
1/29/2025
Several other lawsuits regarding another popular weight loss medication called tirzepatide [brand name Zepbound and Mounjaro] are also ongoing, as its manufacturer, Eli Lilly, has taken a similar legal approach as Novo Nordisk. The FDA
In an emailed statement to The Epoch Times on Friday, the Outsourcing Facilities Association said it was 'deeply disappointed' by the court's decision.
'The U.S. District Court for the Northern District of Texas misapprehended or failed to take into consideration the clear and convincing evidence that demonstrates that the manufactured supply of semaglutide is not able to meet the enormous demand in the U.S.,' said OFA Chairman Lee H. Rosebush.
'We look forward to the opportunity to introduce this evidence again through the legal process and in discussions with the FDA. We will not stop in our efforts to ensure that patients can get access to this vital medication.'
Novo Nordisk said the ruling supports the FDA's conclusion that the supply of its brand-name semaglutide products is sufficient to meet U.S. demand.
'The court's ruling left in place FDA's prior determination that all doses of Wegovy® and Ozempic® are fully available nationwide and that Novo Nordisk's supply of these FDA-approved medicines is meeting or exceeding current and projected nationwide patient demand,' the company said in the statement.
'With the FDA's resolution of the shortage of Ozempic® and Wegovy®, as left in place by this court ruling, it is illegal under U.S. compounding laws to make or sell knockoff 'semaglutide drugs,' with rare exceptions.'
The company said it has filed 111 lawsuits in federal courts across 32 states to stop the marketing and sale of what it describes as knockoff or misbranded compounded versions.
'We are pleased the court has rejected the compounders' attempts to undermine FDA's data-based decision that the shortage of Wegovy® and Ozempic® is resolved,' said Steve Benz, Novo Nordisk's general counsel.
'FDA's determination was based on a thorough review of Novo Nordisk's stable and growing supply of these important FDA-approved medicines. With the end of the shortage of Wegovy® and Ozempic®, no patient should have to be exposed to unsafe, inauthentic 'semaglutide' drugs. Patient safety remains a top priority for Novo Nordisk, and the extensive nationwide legal actions we have taken to protect Americans from the health risks posed by illegitimate 'semaglutide' drugs are working.'
While brand-name drugs such as Ozempic and Wegovy can cost
Novo Nordisk says its legal efforts are aimed at protecting patients from unsafe or unregulated products, including those made with synthetic semaglutide from overseas suppliers, such as manufacturers in China that have not been reviewed by the FDA.
Novo Nordisk and the FDA did not respond to additional questions from The Epoch Times before publication time.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
Natural Grocers® Celebrates National Arkansas Day with a Special Gift and Savings, June 15-17, 2025
Family-Operated grocer offers Arkansas {N}power® members a free state-themed Natural Grocers reusable bag and additional in-store savings LAKEWOOD, Colo., June 11, 2025 /PRNewswire/ -- Natural Grocers®, the leading family-operated organic and natural grocery retailer in the U.S., invites customers to its second annual "Celebrate Arkansas" event, June 15-17, at its three Arkansas locations. In honor of National Arkansas Day, {N}power® members will receive a free, limited-edition, state-themed Natural Grocers reusable bag, and a $5-off coupon toward in-store purchases. NATURAL GROCERS: PROUDLY SERVING THE NATURAL STATEHeadquartered in Colorado, Natural Grocers opened its first store in "The Natural State" in Fayetteville in 2015. Today, the company proudly serves Arkansans at three locations: Fayetteville Jonesboro Little Rock "Natural Grocers started back in 1955 from very humble beginnings. As we expanded beyond our Colorado roots, we were embraced by health-conscious communities seeking high-quality natural and organic products at our Always AffordableSM prices," said Raquel Isely, vice president of marketing for Natural Grocers. "Since opening our first Arkansas store in 2015, we've felt right at home. We're proud to serve Arkansans with products that meet our high standards, which reflect our commitment to the health of humans, the welfare of animals and the principles of regenerative agriculture. That commitment, along with our knowledgeable crew and welcoming atmosphere, is what keeps customers coming back to our stores in Fayetteville, Jonesboro and Little Rock." ARKANSAS {N}POWER® MEMBERS SAVE & CELEBRATE Natural Grocers will be celebrating National Arkansas Day by honoring its customers with a freebie and extra savings for {N}power members from June 15-17, 2025. June 15-17: All {N}power members at all Arkansas stores will receive a FREE, limited-edition, reusable shopping bag featuring each of the 21 states Natural Grocers has a presence in—including Arkansas, while supplies last.[i] June 15-17: {N}power members will enjoy extra savings with a $5 off coupon.[ii] SIGN UP & SAVENot an {N}power member? Not a problem! Discover {N}power, Natural Grocers' free customer rewards program, and enjoy exclusive discounts, deals, and surprise offers. You'll earn valuable rewards points with every visit. Customers can sign up for {N}power here.[iii] Customers can also download the Natural Grocers App for easy access to {N}power benefits and more. A COMMITMENT TO ARKANSAS CREW:Natural Grocers provides careers for over 50 Crew members in the state of Arkansas. The company is passionate about ensuring that its employees can live a healthy, balanced life. Natural Grocers is committed to positively impacting Crew's physical, emotional and financial well-being with free nutrition education programs, excellent benefits and access to the highest quality, affordably priced products. Click here to learn more about career options with Natural Grocers (search by store and state – including Arkansas). LEARN MORE Subscribe to the Free Health Hotline® Magazine to learn more about a natural approach to living with monthly sale items, recipes and educational articles. To keep up with the latest that Natural Grocers has to offer, follow them on Facebook, Instagram, TikTok or YouTube. For media inquiries or sample requests, please email kmacarelli@ ABOUT NATURAL GROCERS BY VITAMIN COTTAGEFounded in 1955, Natural Grocers by Vitamin Cottage, Inc. (NYSE: NGVC) is an expanding specialty retailer of natural and organic groceries, body care products, and dietary supplements. The grocery products sold by Natural Grocers must meet strict quality guidelines and may not contain artificial flavors, preservatives, or sweeteners (as defined by its standards), synthetic colors, or partially hydrogenated or hydrogenated oils. The Company sells only USDA-certified organic produce and exclusively pasture-raised, non-confinement dairy products, and free-range eggs. Natural Grocers' flexible smaller-store format allows it to offer affordable prices in a shopper-friendly, clean, and convenient retail environment. The Company also provides extensive free science-based Nutrition Education programs to help customers and Crew make informed health and nutrition choices. Natural Grocers is committed to its 5 Founding Principles—including its "Commitment to Community" and "Commitment to Crew". In fiscal year 2024, the Company invested more than $15 million in incremental compensation and discretionary payments for Crew. Headquartered in the Union Square neighborhood of Lakewood, CO, Natural Grocers has 169 stores in 21 states. Visit for more information and store locations. [i] Offer available only to {N}power members. Limit one bag per customer. Only valid 6/15/25 to 6/17/25 at participating Arkansas stores, while supplies last. Quantity limited to stock on hand; no rain checks. [ii] Offer available only to registered {N}power members, for in store purchases at participating Arkansas Natural Grocers stores, 6/15/25 to 6/17/25. Customer must load the reward via {N}power email or app prompt before shopping. $5 discount will be applied to product's regular non-discounted price. A minimum purchase of $25 is required to use the $5 off coupon. Must present phone number at checkout to accumulate towards the $25 requirement in one transaction. [iii] Sign up by 6/15/25 to receive this coupon via email or app. {N}power® offers are available only to registered members and are subject to program terms and conditions available at and privacy available at Natural Grocers reserves the right to correct errors. Void where prohibited by law. Natural Grocers employees, including members of their household, are not eligible. View original content to download multimedia: SOURCE Natural Grocers by Vitamin Cottage, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Medscape
2 hours ago
- Medscape
Taletrectinib Approved for NSCLC
The FDA has approved taletrectinib (Ibtrozi, Nuvation Bio) for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) in first- and later-line settings, regardless of prior ROS1 tyrosine kinase inhibitor (TKI) exposure. Taletrectinib is considered a next-generation ROS1 TKI to distinguish it from two first-generation products already on the US market: crizotinib and entrectinib. A third ROS1 TKI approved in 2023, repotrectinib, is also a next-generation medicine. Like repotrectinib, FDA granted taletrectinib a breakthrough therapy designation. Compared with crizotinib and entrectinib, Nuvation Bio data suggests taletrectinib has greater brain penetration, lower incidence of neurologic adverse events, less likelihood of resistance, and other benefits, plus a possible safety and efficacy edge over next-generation rival repotrectinib. 'Taletrectinib will likely become the preferred treatment option for advanced ROS1+ NSCLC,' commented Thomas E. Stinchcombe, MD, an associate editor at the Journal of Clinical Oncology , in the 'Context' section of his journal's publication of a pooled analysis of Nuvation Bio's two approval studies, TRUST-I and TRUST-II, in April. Taletrectinib was originally developed in China and was approved there in Jan 2025 for the same indication granted by FDA. The company plans a US launch in mid-2025, they stated in a press release. About 2% of NSCLC patients have ROS1-positive disease, and about a third of them present with brain metastases. ROS1-positive patients have an oncogenic rearrangement in the ROS1 gene, which leads to an abnormal ROS1 fusion protein that drives cancer growth. ROS1 TKIs block the protein's activity. The drug's approval was based on results of TRUST-I and TRUST-II, phase 2, single-arm, open label studies in ROS1-positive NSCLC patients treated with oral taletrectinib 600 mg once daily until progression, unacceptable toxicity, death, or consent withdrawal. Of the 273 subjects in the pooled analysis, 93.8% had stage IV disease, 33.7% had brain metastases, and 27.1% had received chemotherapy. TRUST-I included Chinese subjects who were either new to TKIs or who had received crizotinib. TRUST-II included patients from North America, Europe, and Asia who were TKI-naive or who had been treated with crizotinib or entrectinib. The efficacy population included 157 patients (103 in TRUST-I; 54 in TRUST-II) who were naive to treatment with a ROS1 TKI and 113 patients (66 in TRUST-I; 47 in TRUST-II) who had received one prior ROS1 TKI. Patients may have received prior chemotherapy for advanced disease. For treatment-naive patients, the overall response rate (ORR) was 90% in TRUST-I and 85% in TRUST-II, with 72% and 63% of responders having a duration of response (DOR) of at least a year, respectively. For TKI-pretreated patients, ORR was 52% in TRUST-I and 62% in TRUST-II, with 74% and 83% of responders having a DOR of at least 6 months, respectively. Among 13 patients with a G2032R mutation, which triggers resistance to first generation ROS1 TKIs, eight (61.5%) had a response to taletrectinib. In a safety analysis with 352 patients, the most frequent treatment-emergent adverse events with taletrectinib were gastrointestinal problems (88%) and elevated aspartate aminotransferase (72%) and alanine aminotransferase (68%). Neurologic adverse events included dizziness (21%) and dysgeusia (15%). Overall, 33% of patients had grade 3 or higher treatment-related adverse events. Treatment-emergent adverse events led to discontinuation in 7% of patients. There were three treatment-related deaths due to abnormal hepatic function, liver failure, and pneumonia. Prescribing information for taletrectinib includes warnings and precautions for hepatotoxicity, interstitial lung disease/pneumonitis, QTc interval prolongation, hyperuricemia, myalgia with creatine phosphokinase elevation, skeletal fractures, and embryo-fetal toxicity. The recommended taletrectinib dose is 600 mg orally once daily on an empty stomach until disease progression or unacceptable toxicity. Taletrectinib pricing was not available, but fourteen 160 mg capsules of rival repotrectinib — the initial 2-week supply with daily dosages doubling afterwards — is $7,666.97, according to
Yahoo
2 hours ago
- Yahoo
AIM ImmunoTech Announces 1-for-100 Reverse Stock Split
OCALA, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (OTC Pink: AIMID) (NYSE American: AIM) ('AIM' or the 'Company') today announced a reverse stock split ('Reverse Stock Split') of its shares at a ratio of 1-for-100. The Reverse Stock Split will take effect at market open tomorrow, June 12, 2025. The Company's ticker symbol on the OTC Pink will be AIMID for 20 trading days, including the effective date. One of the primary goals of the Reverse Stock Split is to increase the per-share market price of the Company's common stock to enable the Company to regain compliance with the NYSE American's Listing Qualifications. At a Special Meeting of Stockholders held on April 30, 2025, the Company's stockholders approved a series of alternate amendments to the Company's Certificate of Incorporation to effect a reverse stock split of the Company's outstanding common stock at a ratio in the range of up to 1-for-100, with such ratio to be determined by the Company's Board of Directors. Stockholders will be given cash in lieu of any fractional shares on a post-split basis. Following the Reverse Stock Split, the new CUSIP number of the common stock will be 00901B303, with the par value per share of common stock remaining at $0.001. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit and connect with the Company on X, LinkedIn, and Facebook. Cautionary Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the 'PSLRA'). Words such as 'may,' 'will,' 'expect,' 'plan,' 'anticipate,' 'continue,' 'believe,' 'potential,' 'upcoming' and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy in any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. CONTACT: Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@